GET THE APP
ISSN: 2471-9552
Erik D’Hondt Head of Research and Development and Regulatory, EU HQ, Bioven Group 33 St James Square LondonUnited Kingdom
Short Communication Pathway Targeted Immunotherapy: Rationale and Evidence of Durable Clinical Responses with a Novel, EGF-directed Agent for Advanced Non-small Cell Lung Cancer Author(s): Erik D’HondtErik D’Hondt DOI: 10.4172/2471-9552.1000134
PDF
